• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BMRN
Held by 2 Gurus
Share

BioMarin Pharmaceutical Inc. Stocks

$ 56.7Last Updated 12.11.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

$ 11.23B

$ 56.7
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.1%

Change

+0.01%

Fund

Bridgewater Associates

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.03%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.1%+0.01%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.03%

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BioMarin Pharmaceutical Inc. operates as a leading biopharmaceutical firm, concentrating on the creation and worldwide commercialization of therapeutic interventions for critical, rare medical conditions and life-threatening diseases. Its market reach extends across the United States, Europe, Latin America, the Middle East, and the Asia Pacific region. The company's current portfolio features several key medications: VIMIZIM, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder. VOXZOGO, a once-daily injectable analog of c-type natriuretic peptide (CNP), approved for achondroplasia. NAGLAZYME, a recombinant form of N-acetylgalactosamine 4-sulfatase, prescribed for patients with MPS VI. PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme, delivered subcutaneously to lower blood Phe levels. BRINEURA, a recombinant human tripeptidyl peptidase 1, indicated for ceroid lipofuscinosis type 2, a type of Batten disease. ALDURAZYME, a purified protein designed to replicate the naturally occurring human enzyme alpha-L-iduronidase. KUVAN, a proprietary synthetic oral variant of 6R-BH4, employed to manage phenylketonuria, an inherited metabolic illness. ROCTAVIAN, an adeno-associated virus (AAV) vector-based treatment for severe hemophilia A. Beyond its marketed products, BioMarin maintains an active development pipeline. This includes BMN 333, a longer-acting CNP aimed at various growth disorders like achondroplasia and hypochondroplasia; BMN 349, an experimental oral therapeutic for liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide under investigation for Duchenne muscular dystrophy. The company's distribution channels encompass specialty pharmacies, hospitals, non-U.S. government entities, distributors, and pharmaceutical wholesalers. BioMarin also holds licensing and collaborative agreements with partners such as Catalyst Pharmaceutical Partners, Inc. and Ares Trading S.A. Established in 1996, the company's corporate headquarters are located in San Rafael, California.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of BMRN is 85.4 and suggests 50.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.11.2026 21:08

Tech Stocks Are Down Again: Nvidia Falls 4%, Nasdaq-100 Drops 2%

13.11.2026 20:50

Burry: The AI bubble began to burst back in the summer. Subtle signals were coming from Nvidia

13.11.2026 20:39

"Things Are Going in the Wrong Direction": U.S. Wholesale Inflation Hits Its Highest Level Since 2022

13.11.2026 20:07

Forbes ranks the 100 most successful U.S. small caps of 2026

13.11.2026 19:49

Cybersecurity stocks failed to sustain their gains amid a Microsoft outage

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026